Axa S.A. Purchases 900,240 Shares of Bristol-Myers Squibb (NYSE:BMY)

AXA S.A. lifted its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 79.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,032,194 shares of the biopharmaceutical company's stock after buying an additional 900,240 shares during the quarter. AXA S.A. owned 0.10% of Bristol-Myers Squibb worth $114,941,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Transce3nd LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Fairway Wealth LLC acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $28,000. Comprehensive Financial Planning Inc. PA bought a new position in shares of Bristol-Myers Squibb in the fourth quarter worth $34,000. Westend Capital Management LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter valued at about $38,000. Finally, Tacita Capital Inc acquired a new stake in Bristol-Myers Squibb in the fourth quarter worth approximately $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,823 shares of the business's stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. The trade was a 2.94 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.09% of the company's stock.

Wall Street Analyst Weigh In

BMY has been the subject of several recent analyst reports. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Piper Sandler started coverage on Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. UBS Group dropped their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Finally, Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Performance

Shares of BMY traded down $2.46 on Tuesday, reaching $47.60. 18,505,635 shares of the company's stock traded hands, compared to its average volume of 13,005,675. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The stock has a market cap of $96.88 billion, a PE ratio of -10.77, a PEG ratio of 2.07 and a beta of 0.39. The stock's 50 day simple moving average is $55.53 and its two-hundred day simple moving average is $56.39. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($4.40) EPS. On average, analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.21%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.